Vertex Q1 2018: The Best Long-Term Story In The Biotech Space


On April 26, 2018, Vertex reported better-than-expected Q1 2018 results , fueled by a solid performance for both Symdeko and Kalydeco. Despite recent outperformance, I still like the company's long-term strategy and its business model, and I believe that shares still offer 40% upside from the current price.



from Biotech News